Oncotype Dx is a test that helps predict the chance of distant recurrence (when cancer spreads to other organs) for lymph node negative, estrogen receptor-positive breast cancers. Oncotype Dx tests a sample of the tumor (removed during a biopsy or surgery) for a group of 21 genes. Along with other prognostic and diagnostic factors, the results of the Oncotype Dx test can be used to tailor treatment plans. If the test shows a person has a fairly high risk of recurrence, a more aggressive treatment plan that includes hormone therapy and chemotherapy may be advised [24,25]. If the test shows a low risk of recurrence, the use of hormone therapy alone may be considered.
More recently, Oncotype Dx has been studied for use in lymph node-positive, estrogen receptor-positive cancers [24,25]. Researchers are also studying whether it can predict how well other types of breast cancer will respond to different types of chemotherapy.
Updated 10/26/09
